Stocks · News reference

CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder

Jul 27, 2026, 11:05 AMBenzinga Newsdesk

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorderRegulatory milestone enables Company to raise up to $50 million through second closing of

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CAMP

Source: benzinga
Observed: Jul 27, 2026, 11:05 AM
Checked: Jul 27, 2026, 11:05 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 10, 2026, 11:37 AMBenzinga Newsdesk
CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and ArgentinaCompany anticipates
CAMP
BenzingaSep 8, 2026, 8:09 PMBenzinga Newsdesk
CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder
CAMP
BenzingaAug 14, 2026, 6:51 PMBenzinga Newsdesk
CAMP4 Therapeutics shares are trading higher after Piper Sandler reiterated its Overweight rating on the stock and raised its price target from $12 to $15.
CAMP
BenzingaAug 14, 2026, 4:22 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15
Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.
CAMP

CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder

Connected Markets

Related Headlines

CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder

CAMP4 Therapeutics shares are trading higher after Piper Sandler reiterated its Overweight rating on the stock and raised its price target from $12 to $15.

Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15